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Lead is one of the most extensively studied 
reproductive toxicants. Several epidemiologic 
studies have demonstrated a positive associa-
tion between blood lead levels and blood pres-
sure among nonpregnant adults (Nawrot et al. 
2002; Schwartz 1995). The evidence is suf-
ficient to infer a causal relationship of lead 
exposure with hypertension (Navas-Acien et al. 
2007). However, the role of lead in pregnancy-
induced hypertension (PIH) remains unclear.
PIH is characterized by an increase in sys-
tolic blood pressure (SBP ≥ 140 mmHg) and/
or diastolic blood pressure (DBP ≥ 90 mmHg) 
after 20 weeks of gestation. This disorder can be 
complicated by proteinuria, a condition corre-
sponding to preeclampsia. PIH is encountered 
in 10% of pregnancies and is an important 
cause of morbidity for both mother and fetus 
(National High Blood Pressure Education 
Program 2000).
Environmental factors may have a role in 
this disease occurrence. Although some studies 
failed to find a relationship between lead con-
centrations in cord blood and pre  eclampsia 
(Angell and Lavery 1982), several authors 
demonstrated higher blood levels of lead, 
cadmium, and manganese in hypertensive 
or preeclampsia patients compared with 
normotensive women (Dawson et al. 2000; 
Kosanovic et al. 2002; Rothenberg et al. 
1999; Vigeh et al. 2004). Other elements 
such as zinc and selenium were reported to 
be reduced in hypertensive pregnant women 
(Dawson et al. 1999; Rayman et al. 2003).
Blood lead levels increase during preg-
nancy, from 24 weeks of gestation until 
delivery, because of increased gastrointesti-
nal absorption and because of an increase in 
bone turnover in this period (Hertz-Picciotto 
et al. 2000; O’Flaherty et al. 1995). Several 
mechanisms may contribute to the patho-
genesis of lead-induced hypertension: increases 
in endothelin and thromboxane production, 
inhibition of vascular smooth muscle ATPases, 
oxidation of endogenous nitric oxide by reac-
tive oxygen species, and a decrease in glomeru-
lar filtration rate of the kidneys with increase 
in the renin–angiotensin II–aldosterone activ-
ity (Gonick and Behari 2002; Vaziri and Khan 
2007; Vaziri and Sica 2004). Interactions 
between lead and other elements are possible 
because oxidative stress produced by lead, 
cadmium, or manganese may be counter-
balanced by the antioxidative properties of 
manganese or selenium (Anastasakis et al. 
2008; Campagna et al. 2000; Huel et al. 2000; 
Vaziri and Sica 2004; Verity 1999).
In the present study, we examined the 
relationship between PIH and circulating 
blood lead, cadmium, manganese, and sele-
nium concentrations in a nonselected popula-
tion of pregnant women.
Materials and Methods
The study population included the first 1,017 
pregnant women enrolled in the EDEN 
(Etude des Déterminants pré et post natals 
du développement et de la santé de l´ Enfant) 
mother–child cohort study counting 2,002 
participants (Drouillet et al. 2008). The num-
ber of subjects needed for the study was based 
on a 10% prevalence of PIH and an estimated 
relative risk of PIH occurrence of 2. No other 
factors influenced the inclusion process.
All women 18–45 years of age who pre-
sented before 24 weeks of gestation for pre-
natal care at two maternity wards in Poitiers 
(western France) and Nancy (eastern France) 
were enrolled if they were able to read and 
write French and were not planning to move 
out of the region. We also excluded women 
who had multiple gestations or a history of 
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ba c K g r O u n D: Prior studies revealed associations of environmental lead exposure with risks of 
hypertension and elevated blood pressure.
Ob j e c t i v e: We examined the effect of blood lead levels on blood pressure and the incidence of 
pregnancy-induced hypertension (PIH) in the second and third trimesters of pregnancy.
Me t h O D s : One thousand seventeen pregnant women were enrolled in two French munici-
palities between 2003 and 2005 for the EDEN (Etude des Déterminants pré et post natals du 
développe  ment et de la santé de l´ Enfant) cohort study. Blood lead concentrations were mea-
sured by atomic absorption spectrometry in mothers between 24 and 28 weeks of gestation.
re s u l t s: PIH was diagnosed in 106 subjects (10.9%). Age, parity, weight gain, alcohol, smoking 
habits, and calcium supplementation were comparable between hypertensive and nonhypertensive 
women. Lead levels were significantly higher in PIH cases (mean ± SD, 2.2 ± 1.4 µg/dL) than in 
normotensive patients (1.9 ± 1.2 µg/dL; p = 0.02). Adjustment for potential confounder effects 
slightly attenuated but did not eliminate the significant association between blood lead levels and 
the risk of PIH (adjusted odds ratio of PIH = 3.3; 95% confidence interval, 1.1–9.7). We also 
observed geographic differences in lead exposure and in the incidence of PIH and found significant 
correlations between blood lead levels and unadjusted as well as adjusted systolic and diastolic blood 
pressures after 24 weeks of gestation.
cO n c l u s i O n s: These findings confirm the relationship between blood lead levels at mid-pregnancy 
and blood pressure and suggest that environmental lead exposure may play an etiologic role in PIH.
Key w O r D s : cadmium, environmental health, epidemiology, gestation, hypertension, lead, 
manganese. Environ Health Perspect 117:1526–1530 (2009).  doi:10.1289/ehp.0800488 avail-
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diabetes. Among women who fulfilled these 
criteria, 55% agreed to participate. The 
study was approved by the Ethic Committee 
of Bicêtre Hospital (November 2002). All 
partici  pants provided informed consent con-
sistent with policies of the INSERM institu-
tional review board. We collected maternal 
blood samples between 24 and 28 weeks of 
gestation, just after the recruitment was vali-
dated by the study midwife. We determined 
blood lead, cadmium, and manganese concen-
trations by electrothermal atomic-absorption 
spectrometry (model 4100 ZL; Perkin-Elmer, 
Courtaboeuf, France) with Zeeman back-
ground correction as previously described 
(Fréry et al. 1993; Huel et al. 1986; Mergler 
et al. 1996). We measured selenium by a stan-
dard fluorometric method as described by Lee 
et al. (1995). We calculated values as means 
of two analyses of each sample, expressed in 
micrograms per deciliter. Internal and external 
quality-control procedures yielded consistently 
satisfactory results. The limit of detection for 
the blood lead measurements was 0.5 µg/dL. 
We assigned a value of 0.5 divided by 2 for 
values less than the limit of detection. Of the 
measured values of blood lead, 2.7% were less 
than the limit of detection.
Gestational age was based on last men-
strual period and/or ultrasound-based esti-
mated date of conception. We divided 
pregnancy into three periods: P1, before 24 
weeks; P2, between 24 and 36 weeks; and P3, 
after 36 weeks of gestation. This choice was 
mainly founded on scientific data regarding 
the incidence of PIH in the second half of 
pregnancy and its frequency with increasing 
gestational age (Groom et al. 2007).
We measured maternal blood pressure 
during routine monthly visits, with the sub-
ject in supine position, using a standard mer-
cury sphygmomanometer.
One set of measures was taken by the 
study midwife between 24 and 28 weeks 
using a different (semiautomated) device, with 
two measurements averaged to determine the 
values for that visit.
Measurements taken within each period 
of gestation (P1, P2, and P3) were averaged 
to determine the values for SBP and DBP 
assigned to each period.
Women were classified as having PIH 
based on SBP ≥ 140 mmHg and/or DBP ≥ 90 
mmHg measured during at least two visits 
after the 22nd week of gestation, such that the 
elevated measures could have occurred during 
or across any of the three periods, at any point 
after 22 weeks. Consequently, no diagnosis of 
PIH was made before 24 weeks.
We gathered medical and reproductive 
histories, clinical follow-up, and delivery data 
from obstetric records. Additional risk factors 
for PIH were obtained using the study ques-
tionnaires presented by trained interviewers to 
subjects during a structured interview. These 
included basic socioeconomic information, 
educational level, and cigarette and alcohol 
use before and during pregnancy. Dietary 
information on consumption of coffee and 
tea and intake of calcium, vitamins, or iron 
supplements was also recorded.
We evaluated socioeconomic status by the 
household monthly income and categorized 
it into three levels (high, > €3,000; medium, 
€1,500 – €3,000; and low, < €1,500). We 
also divided education status into two levels 
(high, ≥ 12 years and low, < 12 years). For the 
analysis of main effects, all variables (except 
for hematocrit) were categorized.
Statistical data analysis was performed 
using SAS software, version 9.1.3 (SAS 
Institute Inc., Cary, NC, USA). We evalu-
ated variables for normality and for out-
liers. Because of skewed distributions, lead, 
cadmium, manganese, and selenium blood 
levels were transformed into their decimal 
logarithms and subsequent geometric means 
were calculated.
Continuous variables were summarized 
by calculating the mean ± SD. Comparisons 
of means or proportions were performed by 
chi-square or Student t-tests as appropriate. 
Cochran-Armitage was used for trend analysis.
We obtained adjusted odds ratios (ORs) 
by means of multivariable logistic regression 
analysis with PIH as the dependent variable. 
We based selection criteria for variables on the 
literature regarding risk factors of PIH. Besides 
all elements measured, adjustment variables 
included maternal age, parity, hemato  crit, 
body mass index (BMI), pregnancy weight 
gain, gestational diabetes, educational level, 
socioeconomic status, geographic residence 
(maternity ward), and smoking status and 
alcohol consumption before and during preg-
nancy. Although we used stepwise procedure 
to ascertain percentage of variance attribut-
able to selected variables, relevant risk factors 
were forced into the final model. We tested 
interaction terms between blood lead levels 
(as a continuous variable) and other maternal 
variables with a significance level reduced to 
0.005 (according to the Bonferroni method). 
Otherwise, p-value < 0.05 was considered to 
indicate statistical significance.
Pearson partial correlations were calcu-
lated between blood lead levels and SBP and 
DBP during the three periods of pregnancy.
Results
Among the 1,017 women in the study popula-
tion, we excluded 31 records (3.0%) because of 
insufficient sample volumes or analytical prob-
lems in metal measurements, and 15 records 
(1.5%) because of chronic hypertension under 
treatment before pregnancy. This left a study 
group of 971 pregnant women. Mothers’ mean 
age was 29.3 ± 4.9 years. PIH occurred in 106 
(10.9%) women and was complicated by pro-
teinuria (preeclampsia) in 20 (2.1%) cases.
In Table 1 we summarize the character-
istics of the cohort in relation to PIH occur-
rence. Compared with the normotensive 
group, women who developed PIH presented 
a higher BMI before pregnancy (21.9% vs. 
6.3%, p < 0.001) and a higher hematocrit level 
(35.2% vs. 34.6%, p = 0.02). They presented 
more frequently with gestational diabetes 
(17.0% vs. 5.9%, p < 0.001) and premature 
delivery (13.2% vs. 5.0%, p < 0.001). The 
incidence of PIH was significantly higher in 
Nancy than in Poitiers (63.2 vs. 36.8% of PIH 
patients, p < 0.001, respectively). PIH was also 
negatively associated with birth weight. There 
were very few missing covariate data (< 3.8% 
in the PIH group and < 5.2% among women 
without PIH for most of the variables stud-
ied).
Mean blood lead concentration in the 
PIH group (2.2 ± 1. 4 µg/dL; range, 0.2–8.5 
µg/dL) was significantly higher than that 
of normotensive women (1.9 ± 1.2 µg/dL; 
range, 0.2–6.9 µg/dL; p = 0.02). Mean man-
ganese concentration was slightly higher in 
PIH women but did not reach significance. 
Cadmium and selenium blood concentrations 
were comparable between groups (Table 2).
The frequency of PIH was lowest among 
women whose blood lead concentrations 
were in the lowest quartile (7.7%) and was 
significantly greater in the second (10.7%), 
third (11.1%), and fourth exposure quartiles 
(13.1%; p = 0.03 for trend). The unadjusted 
OR of PIH associated with an increase of 1 µg/
dL in maternal blood lead levels was 3.5 [95% 
confidence interval (CI), 1.4–8.9].
Adjustment for a range of characteristics 
and elements (cadmium, manganese, and 
selenium blood concentrations; hematocrit 
level; maternal age; BMI; parity; gestational 
diabetes; education and socioeconomic level; 
and smoking status and geographic residence) 
slightly attenuated but did not eliminate the 
significant association between blood lead lev-
els and the risk of PIH (Table 3). Adjusted 
OR of PIH for an increase of 1 µg/dL in 
maternal blood lead levels was estimated at 
3.3 (95% CI, 1.1–9.7). We observed no sig-
nificant interactions among blood lead levels, 
any of the other elements, and the maternal 
characteristics in predicting the risk of PIH.
Furthermore, excluding women with 
preeclampsia (n = 20) attenuated the asso-
ciation between blood lead levels and PIH 
(adjusted OR = 3.1; 95% CI, 1.0–10.0).
When stratified by parity (Table 4), blood 
lead levels were higher in multiparous than in 
nulliparous women (2.0 ± 1.2 µg/dL vs. 1.8 ± 
1.3 µg/dL, respectively; p = 0.003). Adjusted 
OR for PIH was increased to 4.6 (95% CI, 
1.0–21.6) in multiparous compared with 2.9 
(95% CI, 0.6–15.7) in nulliparous women. Yazbeck et al.
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There was no interaction between parity and 
blood lead (p = 0.46).
Log-transformed blood lead at mid-preg-
nancy was significantly correlated with both 
SBP (r = 0.08; p = 0.03) and DBP (r = 0.07; 
p = 0.03) after 24 weeks of gestation (P2), 
and this correlation remained significant after 
36 weeks (P3). Figure 1 illustrates correla-
tion between residuals of the linear regression 
of maternal blood lead and SBP at P2 on 
the partialed variables. Lead concentrations 
accounted for approximately 5% of the total 
unexplained variance obtained by linear mod-
els. Each decimal-log increase in blood lead 
was associated with an increase of 3.5 mmHg 
in SBP and of 2.5 mmHg in DBP during the 
second half of pregnancy.
Discussion
We found that the adjusted risk of PIH was 
associated with maternal blood lead levels in 
mid-pregnancy. This risk was doubled in the 
highest quartile compared with the lowest 
quartile of lead distribution. There was no 
strong evidence of an interaction between 
lead and cadmium, manganese, selenium, or 
other factors associated with the risk of PIH. 
The risk of PIH increased with increasing 
absolute values of mid-pregnancy blood lead 
in a “dose–response” pattern. A positive cor-
relation was particularly found with SBP at 
P2 after 24 weeks and persisted after 36 weeks 
of gestation with SBP at P3. All these findings 
suggest that blood lead level may be one of 
the causal factors of PIH.
Evidence has been given that lead increases 
the circulating levels of endothelin, a vasoactive 
substance secreted by endothelial cells (Gonick 
and Behari 2002). Lead is also reported to 
reduce levels of vasodilator substances such as 
plasma nitric oxide and endothelial-derived 
relaxation factor; this reduction is due to a 
lead-mediated increase in reactive oxygen 
species (Carmignani et al. 2000; Gonick and 
Behari 2002; Gonick et al. 1997). Inhibition 
of membrane ATPases by this metal also 
leads to increased intracellular calcium ions 
and vasoconstriction (Moreau et al. 1988). 
Furthermore, a demonstrable inhibitory effect 
of lead on blood enzymes such as delta-amino-
levulinic acid dehydratase activity was found 
at a low threshold of lead exposure, ranging 
from 3.2 to 4.8 µg/dL (Campagna et al. 1999; 
Telisman et al. 2004). From the above argu-
ments, it may be hypothesized that environ-
mental exposure to lead increases the risk of 
PIH by inducing vasoconstriction and pla-
cental ischemia or by a direct toxicity on the 
endothelial cell and the renal function.
Our findings are consistent with those 
from previous studies showing a relationship 
between blood lead levels and PIH. However, 
most of these reports analyzed lead concentra-
tions late in pregnancy, from maternal pre-
natal red blood cells (Dawson et al. 2000), 
umbilical cord (Rabinowitz et al. 1987), amni-
otic fluid (Dawson et al. 1999), or maternal 
blood within 24 hr after delivery (Vigeh et al. 
2004, 2006). Our study did not involve serial 
measurements of blood lead levels throughout 
pregnancy. However, the optimal period for 
such measurement would be in the second tri-
mester (24 weeks of gestation), at the begin-
ning of a potential pathologic change in blood 
Table 1. Baseline characteristics according to PIH occurrence among 971 pregnant women with no his-
tory of chronic hypertension.
Characteristic PIH No PIH p-Value
Maternal age (%)  0.70
  < 25 years 19.8 17.6
  25–34 years 64.2 68.2
  ≥ 35 years 16.0 14.2
  No. 106 865
Education (%) 0.87
  ≥ 12 years 64.2 66.2
  < 12 years 30.2 29.0
  Unknown 5.7 4.7
  No. 106 865
Socioeconomic status (%)  0.76
  High 25.7 25.5
  Medium 52.4 55.5
  Low 21.9 19.0
  No. 105 851
Geographic residence (%)  < 0.001
  Poitiers (western) 36.8 58.6
  Nancy (eastern) 63.2 41.4
  No. 106 865
Hematocrit, (mean ± SD)a  35.2 ± 2.5 34.6 ± 2.6 0.02
  No. 105 842
BMI before pregnancy (%)  < 0.001
  < 25 53.3 76.2
  25–29.9 24.8 17.5
  ≥ 30 21.9 6.3
  No. 105 835
Weight gain during pregnancy [kg (mean ± 
SD)] 
13.4 ± 6.5 13.4 ± 4.6 0.92
  No. 104 834
Gestational diabetes (%) < 0.001
  No 83.0 94.1
  Yes 17.0 5.9
  No. 106 851
Parity (%) 0.71
  Nulliparous 42.5 44.3
  Multiparous 57.5 55.7
  No. 106 848
Smoking during pregnancy (%) 0.86
  0 cigarettes/day 72.6 71.7
  ≥ 1 cigarette/day 27.4 28.3
  1–9 cigarettes/day 19.6 22.2
  ≥ 10 cigarettes/day 7.8 6.1
  No. 102 820
Alcohol consumption before pregnancy (%)  0.90
  No 28.2 28.7
  Yes 71.8 71.3
  No. 103 849
Iron/calcium supplementation (%) 0.95
  No 2.8 3.9
  Yes 61.3 60.1
  Unknown 35.9 36.0
  No. 106 865
Premature delivery [before 37 weeks (%)]  < 0.001
  No 86.8 95.1
  Yes 13.2 5.0
  No. 106 851
Neonate weight [g (mean ± SD)] 3126.7 ± 
719.9
3299.0 ± 493.6 0.02
  No. 106 844
Neonate sex (%)  0.28
  Male 58.5 52.9
  Female 41.5 47.1Lead and gestational hypertension
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pressure. Moreover, models on lead varia-
tion during pregnancy described a constant 
increase in blood lead levels from 24 weeks 
of gestation until delivery (O’Flaherty et al. 
1995). Indeed, longitudinal analyses showed 
that maternal blood lead concentrations upon 
entering prenatal care (average of 13.5 weeks) 
were not associated with PIH, whereas higher 
lead levels during the second trimester were 
related to PIH (Sowers et al. 2002).
The severity of the outcome (i.e., pre-
eclampsia) may be related to the magnitude of 
lead exposure because we discovered a weaker 
association between blood lead and PIH when 
excluding women with preeclampsia. This 
finding further supports the likelihood of a 
dose–response relation between blood lead 
and hypertension.
Our analysis of correlations of SBP at P2/P3 
and DBP at P2/P3 with blood lead concentra-
tions was consistent with that of previous studies 
on essential hypertension (Batuman et al. 1983). 
Recent reviews suggest a weak but dependable 
association between lead levels and blood pres-
sure. The increase in SBP is estimated between 
0.8 and 2.0 mmHg (Hertz-Picciotto and Croft 
1993; U.S. Environmental Protection Agency 
2006). We excluded chronic hypertension from 
our study because of risks of bias associated to 
prior treatment with antihypertensive drugs. 
This exclusion might have attenuated the corre-
lation between blood lead and blood pressure.
Manganese blood level was not significantly 
associated with PIH in this study, although 
there was some evidence of a possible weak 
association. The underlying mechanisms of 
manganese-induced hypertension are probably 
independent from gestational age. The decrease 
in blood manganese with intrauterine growth 
restriction might obscure any other pathologic 
effect (Vigeh et al. 2008). Cadmium also was 
not significantly associated with PIH in the 
present model. This finding may be related to 
relatively low levels of cadmium observed in 
this cohort. These reduced levels were probably 
due to the low prevalence of smoking, which 
is the main environmental source of cadmium 
(Bonithon-Kopp et al. 1986). Interaction 
between selenium and lead concentrations 
were not significant, and the putative protec-
tive effect of selenium through antioxidative 
properties was not confirmed in this study.
Hematocrit levels are usually elevated in 
pregnancy hypertensive disorders (Goldstein 
et al. 2000). This may be due to a lower water 
balance index correlated to stroke volume or 
to a lower venous capacitance in hypertensive 
patients (Aardenburg et al. 2005). Increases 
in hematocrit automatically increase blood 
lead, which is concentrated in red blood cells. 
Although we found no statistical interaction 
between blood lead and hematocrit, potential 
confounding can not be ruled out. 
BMI was strongly associated with PIH. 
This finding is consistent with that of previous 
reports (Hrazdilova et al. 2001; Vigeh et al. 
2006). A dose–response relationship has also 
been observed in this study, so BMI before 
pregnancy should be considered in all mod-
els including PIH. The effect of gestational 
diabetes on PIH was limited in the multi-
variate regression analysis probably because of 
its association with increased BMI.
Age and parity were not significant covari-
ates in this study. Although a trend of increas-
ing blood pressure with age is usually reported 
for DBP, the restricted age range (18–45 years) 
and the limited number of women > 40 years 
of age in the present study may have reduced 
our ability to highlight an age effect on PIH.
As to parity, high levels of blood lead 
observed in multiparous women of this study 
may have contributed to an increase in the 
frequency of PIH in this group, thus reducing 
the difference usually observed in the incidence 
of PIH and preeclampsia depending on par-
ity. Moreover, data obtained from systematic 
ambulatory monitoring in a large sample of 
normotensive pregnant women indicate the 
lack of differences in blood pressure according 
to parity (Ayala and Hermida 2001).
Finally, PIH frequency was higher in 
Nancy than in Poitiers. A separate analysis 
(data not shown) revealed higher blood lead 
levels in Nancy (2.0 ± 1.3 µg/dL) than in 
Poitiers (1.8 ± 1.1 µg/dL; p < 0.001). Thus, 
a major difference in the incidence of PIH 
between these two regions might have been 
their history of environmental exposure to 
chemical pollutants. Blood lead level primarily 
reflects recent exposure, although a part of lead 
in blood may originate from lead stored in 
bone, particularly during pregnancy (Gulson 
et al. 1997). Because bone lead has a half-life 
of years to decades, the higher blood lead lev-
els observed in eastern versus western region 
reflect differences in current exposure, but 
may also reflect some differences in past expo-
sure, or both. Hence, the relationship between 
blood lead and blood pressure may be medi-
ated by the contribution of bone lead to blood 
lead, placing a larger amount of bioavailable 
Figure 1. Scatterplot of the residuals for mater-
nal blood lead and SBP between 24 and 36 weeks 
(P2) after controlling for the effect of variables 
listed in the logistic model in Table 3: correlation 
between residuals of the linear regression of the 
two variables on the partialed variables. In the 95% 
and 70% prediction ellipses, the major axis length 
is significantly larger than the minor axis length, 
indicating a partial correlation between maternal 
blood lead and SBP at P2. 
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Table 2. Distribution level of elements in maternal blood at mid-pregnancy, according to PIH occurrence.
PIH (n = 106) No PIH (n = 865)
Element
Mean ± 
SD Geometric mean
Mean ± 
SD Geometric mean p-Valuea
Lead (µg/dL) 2.2 ± 1.4 b 1.9 1.9 ± 1.2 1.6 0.02
Cadmium (µg/L) 0.9 ± 0.5 0.8 0.9 ± 0.6 0.7 0.08
Manganese (µg/L) 11.8 ± 6.3 10.6 10.6 ± 4.5 9.6 0.06
Table 3. ORs for PIH, according to maternal blood lead distribution and overall outcome characteristics.
Unadjusted analysis Adjusted analysisa
Quartile OR (95% CI) p-Value OR (95% CI) p-Value
Log (lead)b  3.49 (1.37–8.87) 0.009 3.29 (1.11–9.74) 0.03
Q1 (referent) 1.0 1.0
Q2 1.55 (0.78–3.11) 0.94 1.84 (0.77–4.41) 0.84
Q3 1.61 (0.78–3.31) 0.81 2.07 (0.83–5.13) 0.50
Q4 2.19 (1.09–4.41) 0.06 2.56 (1.05–6.22) 0.09
Number of observations used in adjusted analysis: 720; convergence criterion satisfied; R2 = 15.7%. Quartiles of maternal 
blood lead distribution: Q1, < 1.20 µg/dL; Q2, 1.20–1.70 µg/dL; Q3, 1.71–2.30 µg/dL; Q4, > 2.30 µg/dL. aAdjusted for maternal 
age; cadmium, manganese, and selenium blood levels; hematocrit; parity; BMI; gestational diabetes; educational level; 
socioeconomic status; geographic residence; and smoking status during pregnancy. bLog-transformed maternal blood 
lead used as a continuous variable. 
Table 4. ORs for PIH according to parity, per unit 
increase in blood lead level.
Measure Nulliparous Multiparous
PIH incidence (%) 10.7 11.4
Unadjusted OR (95% CI) 1.8 (0.5–6.6) 3.7 (1.1–12.3)
Adjusted ORa (95% CI) 2.9 (0.6–15.7) 4.6 (1.0–21.6)
aAdjusted for maternal age; cadmium, manganese, and 
selenium blood levels; hematocrit; BMI; gestational 
diabetes; educational level; socioeconomic status; 
geographic residence; smoking status and alcohol con-
sumption before pregnancy.Yazbeck et al.
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lead into tissues and organs that affect blood 
pressure (Rothenberg et al. 1999).
The main sources of measurement 
errors of blood pressure are the inaccuracy 
of meas  ure  ment methods and the intrain-
dividual variability of blood pressure. We 
attempted to minimize these effects by 
averaging all blood pressure measurements 
available in the   obstetric files.
Although the association between blood 
lead levels and PIH persisted in the multivari-
ate analysis, it is also possible that it reflects 
residual confounding due to unmeasured con-
founders. Geographic residence is a general 
covariate, and residual confounding by this 
variable cannot be ruled out. However, if this 
residual confounding explained the association 
found in the multivariate analysis, it is likely 
that an interaction between geographic resi-
dence and blood lead levels would have been 
observed. Moreover, blood lead concentration 
may be a better estimate of maternal environ-
mental exposure than external indicators, and 
its use as a continuous variable in the regression 
model limits the risk of residual confounding.
PIH remains a multifactor disease with 
unclear etiology, which could compromise 
maternal reproductive and newborn out-
comes. We identified a significant association 
between maternal blood lead levels in mid-
pregnancy and blood pressure. Our findings 
suggest that lead may have an etiologic role 
in PIH, even at low levels of environmental 
exposure, and thus incite public health orga-
nizations to revise the upper limit of “accept-
able” blood lead levels in pregnant women, 
which is currently at 10 µg/dL.
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